The Fibromyalgia Antidepressants Market is expected to make technological advancement-based strides in the forecast period. The businesses are converting their physical aspects into technology-based ones, that too, digital technology-based! IoT platforms are there to help in the creation of the digital twin of almost every physical object, thereby easing the lifecycle of the product. Extending the point, IoT data is being extensively used for supporting sales as well as service departments. This is indeed a kick-start! The future is there to witness digital adventures.

As per Persistence Market Research’s latest industry analysis, the global fibromyalgia antidepressants market was valued at US$ 440.8 Mn in 2020, and is expected to exhibit a healthy CAGR of 8.1% over the forecast period (2021-2031)

Rising prevalence of fibromyalgia caused due chronic back pain, previously associated spinal injury, trauma, osteoarthritis, road accidents, and musculoskeletal disorders are expected to drive demand for better treatment along with effective medications for fibromyalgia. Thus, demand for improved treatment with fibromyalgia antidepressants is expected to provide a positive impetus to market growth.

Treatment cost with branded drugs is significantly higher, and it is expected to remain high when compared with generic drugs or other off-label drugs. These higher costs will drive demand for generic drugs. The generic versions of these drugs are likely to see high demand in low-income economies or in economies where these products are limited or not available.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32898

Consolidation activities, mergers, and acquisitions have emerged as a key growth strategy among industry leaders. This trend is quite evident in key markets for fibromyalgia antidepressants.

• For instance, the recent acquisition of Allergan plc by AbbVie Inc. in May 2020. This acquisition enabled AbbVie to strengthen its presence across key therapy areas, including immunology, hematologic oncology, and neuroscience.
• Similarly, in June 2019, Eli Lily received FDA approval for its migraine drug Emgality, for its use in the treatment in management of cluster headaches.

Company Profiles:

• Pfizer, Inc.
• Eli Lilly and Company.
• AbbVie, Inc
• TONIX Pharmaceuticals Holdings Corp
• Virios Therapeutics, Inc.
• Aptinyx Inc.

Get A Customized Scope To Match Your Need Ask An Expert –  sales@persistencemarketresearch.com

Key Takeaways from Market Study

• In terms of drug class, duloxetine HCL drug holds around 57.8% market value share. Growth is primarily attributed as duloxetine HCL mainly used to treat patients with diabetes and long-term chronic pain.
• Based on distribution channel, hospitals pharmacies are leading with over 46% market share, as more patients are consulted at hospitals for fibromyalgia.
• By region, North America is set dominate the global market with a value share of around 45.8% in 2021. Europe is slated to be the second-largest leading regional market with a value share of around 20.5% in 2021.

“Rising number of cases of fibromyalgia and better availability of fibromyalgia antidepressant medication are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/32898

Market Competition

New product launches and approvals, agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

• In January 2021, Eli Lilly acquired pharmaceutical rights from Aashi Kahei Pharma of its experimental drug in early-stage testing for managing chronic pain.
• In October 2020, Eli Lily entered into a collaboration agreement with Daichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody, which has potential use in the treatment of migrane.
• In July 2019, FSD BioSciences, Inc. acquired a U.S.-based company Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia anti-depressants market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on the drug class (venlafaxine, duloxetine HCL, milnacipran HCL, and others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online sales), and seven key regions of the world.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com